Literature DB >> 27891374

Effect of Enhanced External Counter Pulsation Treatment on Aortic Blood Pressure, Arterial Stiffness and Ejection Fraction in Patients with Coronary Artery Disease.

Ramasamy Subramanian1, Sushma Nayar2, Chokkalingam Meyyappan3, N Ganesh3, Arumugam Chandrakasu3, Pradeep G Nayar4.   

Abstract

INTRODUCTION: Enhanced External Counter Pulsation (EECP) is a non-invasive treatment option for patients with Coronary Artery Disease (CAD). The treatment has shown to augment diastolic pressure and reduce Left Ventricular (LV) after-load by reducing systemic vascular resistance. The effect of EECP in standard brachial blood pressure and central haemodynamic parameters are not known. AIM: We hypothesized that EECP may have differential effect in CAD patients with low systolic blood pressure when compared to normal systolic pressure and the mechanism underlying this differential effect may be due to improvement in LV function.
MATERIALS AND METHODS: A total of 72 consecutive patients who underwent EECP treatment for symptomatic CAD with LV dysfunction were divided into two groups based on cut-off value of 100mmHg for systolic blood pressure. First group had patients with brachial systolic blood pressure of >100mmHg and second group had patients with brachial systolic blood pressure of ≤100mmHg. We measured central aortic systolic pressure, pulse pressure, augmentation index and augmentation pressure by SphygmoCor device and Ejection Fraction (EF) was measured by echo-cardiography. All these measurements were carried out prior to and after completion of 35 days of EECP sessions.
RESULTS: Central systolic pressure, brachial systolic pressure, aortic pulse pressure, augmentation pressure and augmentation index significantly decreased in patients with normal brachial systolic pressure with baseline moderate LV dysfunction. Brachial systolic, aortic systolic and aortic pulse pressure significantly increased with no change in augmentation index and pressure is observed in patients with baseline severe LV dysfunction associated with low systolic pressure post EECP treatment.
CONCLUSION: EECP treatment has haemodynamically favourable differential effect in normal and low brachial systolic pressure and this is mainly driven by improvement in LV function in patients with symptomatic CAD with LV dysfunction.

Entities:  

Keywords:  Augmentation index; Central systolic pressure; Left ventricular dysfunction

Year:  2016        PMID: 27891374      PMCID: PMC5121712          DOI: 10.7860/JCDR/2016/23122.8743

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  17 in total

1.  Left ventricular systolic unloading and augmentation of intracoronary pressure and Doppler flow during enhanced external counterpulsation.

Authors:  Andrew D Michaels; Michel Accad; Thomas A Ports; William Grossman
Journal:  Circulation       Date:  2002-09-03       Impact factor: 29.690

2.  Enhanced external counterpulsation improves exercise duration and peak oxygen consumption in older patients with heart failure: a subgroup analysis of the PEECH trial.

Authors:  Charles W Abbottsmith; Eugene S Chung; Thomas Varricchione; Paul-Andre de Lame; Marc A Silver; Gary S Francis; Arthur M Feldman
Journal:  Congest Heart Fail       Date:  2006 Nov-Dec

3.  Improvement of fractional flow reserve and collateral flow by treatment with external counterpulsation (Art.Net.-2 Trial).

Authors:  E E Buschmann; W Utz; N Pagonas; J Schulz-Menger; A Busjahn; J Monti; W Maerz; F le Noble; L Thierfelder; R Dietz; V Klauss; M Gross; I R Buschmann
Journal:  Eur J Clin Invest       Date:  2009-07-02       Impact factor: 4.686

4.  Effects of enhanced external counterpulsation on stress radionuclide coronary perfusion and exercise capacity in chronic stable angina pectoris.

Authors:  Tomasz P Stys; William E Lawson; John C K Hui; Bruce Fleishman; Karen Manzo; John E Strobeck; Joseph Tartaglia; Subramanian Ramasamy; Raymond Suwita; Zhen Sheng Zheng; Hong Liang; Dierk Werner
Journal:  Am J Cardiol       Date:  2002-04-01       Impact factor: 2.778

5.  Impact of enhanced external counterpulsation on Canadian Cardiovascular Society angina class in patients with chronic stable angina: a meta-analysis.

Authors:  Sachin A Shah; Robert J Shapiro; Rina Mehta; Jeffrey A Snyder
Journal:  Pharmacotherapy       Date:  2010-07       Impact factor: 4.705

6.  Long-term prognosis of patients with angina treated with enhanced external counterpulsation: five-year follow-up study.

Authors:  W E Lawson; J C Hui; P F Cohn
Journal:  Clin Cardiol       Date:  2000-04       Impact factor: 2.882

7.  Exercise capability and myocardial perfusion in chronic angina patients treated with enhanced external counterpulsation.

Authors:  J Tartaglia; J Stenerson; R Charney; S Ramasamy; B L Fleishman; P Gerardi; J C K Hui
Journal:  Clin Cardiol       Date:  2003-06       Impact factor: 2.882

8.  Successful treatment of symptomatic coronary endothelial dysfunction with enhanced external counterpulsation.

Authors:  Piero O Bonetti; Suresh N Gadasalli; Amir Lerman; Gregory W Barsness
Journal:  Mayo Clin Proc       Date:  2004-05       Impact factor: 7.616

9.  Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease.

Authors:  Piero O Bonetti; Gregory W Barsness; Paul C Keelan; Theresa I Schnell; Geralyn M Pumper; Jeffrey T Kuvin; Robert P Schnall; David R Holmes; Stuart T Higano; Amir Lerman
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

Review 10.  Enhanced external counterpulsation and future directions: step beyond medical management for patients with angina and heart failure.

Authors:  Aarush Manchanda; Ozlem Soran
Journal:  J Am Coll Cardiol       Date:  2007-10-01       Impact factor: 24.094

View more
  1 in total

Review 1.  Enhanced external counterpulsation: A unique treatment for the "No-Option" refractory angina patient.

Authors:  Jose Caceres; Patricia Atal; Rohit Arora; Derek Yee
Journal:  J Clin Pharm Ther       Date:  2021-01-07       Impact factor: 2.512

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.